Based on the analysis above, we believe that Gilead stock is a buy for the long term, as the company has a strong cash flow and a diversified pipeline, which could offset the challenges of its declining HIV franchise and its competitive landscape.
The company also has several growth opportunities in the oncology market, as well as a strategic partnership with Merck for its HIV program. The company faces some regulatory uncertainty and legal risk, but these are unlikely to have a material impact on its financial performance and outlook.
